Pieta W. Bruggink‐André de la Porte

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

Dirk J. Lok, Peter van der Meer, Pieta W. Bruggink‐André de la Porte et al. · Clinical Research in Cardiology · 2010 · 465 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure

Dirk J. Lok, Sjoukje I. Lok, Pieta W. Bruggink‐André de la Porte et al. · Clinical Research in Cardiology · 2012 · 214 citations · Full text

Medicine, Cardiology, Physiology +13

Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15, High-Sensitivity C-Reactive Protein, Galectin-3, and High-Sensitivity Troponin-T) in Patients With Advanced Chronic Heart Failure

Dirk J. Lok, IJsbrand T. Klip, Sjoukje I. Lok et al. · The American Journal of Cardiology · 2013 · 96 citations · Full text

Medicine, Cardiology, Clinical Cardiology +12

Prognostic Value of N-Terminal Pro C-Type Natriuretic Peptide in Heart Failure Patients with Preserved and Reduced Ejection Fraction

Dirk J. Lok, IJsbrand T. Klip, Adriaan A. Voors et al. · European Journal of Heart Failure · 2014 · 52 citations · Full text

Medicine, Cardiology, Internal Medicine +8

Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value

Sjoukje I. Lok, D. J. A. Lok, Petra van der Weide et al. · Netherlands Heart Journal · 2014 · 11 citations · Full text

Medicine, Cardiology, Pharmacology +16